United Laboratories Stock and Its China Diabetes Drug Filing Means For Shareholders

Simply Wall St.10-01

United Laboratories International Holdings reported that China’s National Medical Products Administration accepted the marketing registration application for its self-developed IDegLira biosimilar, a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672403738?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-10-01 02:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672403738","market":"sg","top_or_hot":-1,"title":"United Laboratories Stock and Its China Diabetes Drug Filing Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>United Laboratories International Holdings reported that China’s National Medical Products Administration accepted the marketing registration application for its self-developed IDegLira biosimilar, a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-stock-and-its-china-diabetes-drug-filing\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Laboratories Stock and Its China Diabetes Drug Filing Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Laboratories Stock and Its China Diabetes Drug Filing Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-01 02:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-stock-and-its-china-diabetes-drug-filing><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>United Laboratories International Holdings reported that China’s National Medical Products Administration accepted the marketing registration application for its self-developed IDegLira biosimilar, a ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-stock-and-its-china-diabetes-drug-filing\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-stock-and-its-china-diabetes-drug-filing","article_id":"2672403738","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3933/united-laboratories-international-holdings-shares/news/united-laboratories-stock-and-its-china-diabetes-drug-filing","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672403738","pubTimestamp":1790792746,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"United Laboratories International Holdings reported that China’s National Medical Products Administration accepted the marketing registration application for its self-developed IDegLira biosimilar, a once daily fixed dose insulin degludec and liraglutide combination for type 2 diabetes.\nThis filing positions United Laboratories as the first domestic producer in China to seek approval for an IDegLira biosimilar. It could reshape the company’s diabetes portfolio by tying long acting glucose...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK4211":"区域性银行","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","BK1191":"制药","UBCP":"联合合众银行"},"translate_title":"联邦制药股票及其股东中国糖尿病药物备案方式","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":0.9,"UBCP":1.5},"content_text":"United Laboratories International Holdings reported that China’s National Medical Products Administration accepted the marketing registration application for its self-developed IDegLira biosimilar, a once daily fixed dose insulin degludec and liraglutide combination for type 2 diabetes. This filing positions United Laboratories as the first domestic producer in China to seek approval for an IDegLira biosimilar. It could reshape the company’s diabetes portfolio by tying long acting glucose control to a simplified dosing schedule. We will now look at how United Laboratories' investment narrative could shift as it pursues first mover IDegLira biosimilar status.  Scan beyond United Laboratories International Holdings and compare this first mover IDegLira story with other drug makers pushing for defensible moats in diabetes and chronic care through our curated 133 healthcare AI stocks AdvertisementWhat Is United Laboratories International Holdings' Investment Narrative? To own United Laboratories International Holdings, you need to believe in a China centered pharma platform that can keep turning a broad mix of bulk medicine, intermediates, and finished drugs into durable cash flow while managing capital heavy manufacturing. The IDegLira biosimilar filing fits that thesis. It shows the group is willing to invest in more complex, higher value chronic care products rather than rely only on commoditised antibiotics and older therapies. In the near term, the key swing factors remain very operational. Execution on R&D, regulatory timelines, and the ability to defend pricing in a crowded diabetes arena matter more than storytelling. Profitability is a pressure point, with net profit margins at 4.5% compared with 21.7% last year. The stock has fallen 45% over the past year despite a P/E of 24.8x, which sits below the peer average of 30.1x but above both the sector and one fair value estimate. The IDegLira news therefore arrives into a market that is already skeptical about how efficiently United Laboratories can turn its pipeline into returns. That said, there is one awkward tension in the United Laboratories story that only really shows up once you focus on ... There's only one way to know the right time to buy, sell or hold United Laboratories International Holdings. Head to Simply Wall St's company report for the latest analysis of United Laboratories International Holdings's Fair Value. SEHK:3933 1-Year Stock Price Chart Exploring Other Perspectives Two fair value estimates from the Simply Wall St Community span an extreme range, from about HK$0.000044 to HK$12.88, which shows how far views on United Laboratories International Holdings can stretch. Since neither figure reflects the recent IDegLira filing, treat this as a starting point and explore more community perspectives before forming a view. Explore another United Laboratories International Holdings fair value estimate, including one that suggests as much as 100% downside from the current price! Form Your Own Verdict Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your United Laboratories International Holdings research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. See our latest analysis for United Laboratories International Holdings. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate United Laboratories International Holdings' overall financial health at a glance.  Looking For More Investment Ideas Beyond United Laboratories International Holdings? If the United Laboratories International Holdings story has sharpened your view on risk, reward, and pricing power in healthcare, it can help to widen the lens and compare it with other businesses that share some of those traits but sit in very different positions on quality, income potential, or balance sheet strength.  For investors who want lower drama and steadier fundamentals, consider scanning a 226 resilient stocks with low risk scores that may better fit a more conservative approach. If value is the priority and you are hunting for mispriced opportunities, line up United Laboratories International Holdings against a 189 high quality undervalued stocks to see where the risk and return trade offs look more attractive. Income focused portfolios can benefit from comparing United Laboratories' profile with a 156 dividend fortresses that screens for stronger yield support and consistency.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672403738","isCrawlerRequest":true}